The Food and Drug Administration (FDA) has approved Tecentriq Hybreza ™ (atezolizumab and hyaluronidase-tqjs) for subcutaneous (SC) injection, for all the approved adult indications of intravenous ...
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results